<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064073</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001102</org_study_id>
    <nct_id>NCT04064073</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study)</brief_title>
  <official_title>A Randomized, Open Label, Single / Multiple Dose, Crossover Phase 1, Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate drug-drug interaction of DWP16001 in combination
      with metformin IR 1000mg in Healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of DWP16001</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Peak Plasma Concetration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DWP16001</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Metformin</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Peak Plasma Concetration at steady-state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss of Metformin</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Area under the plasma concentration versus time curve at Tau, steady-state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of DWP 16001, Metformin, DWP16001 Metabolites</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Time at Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of DWP 16001, Metformin, DWP16001 Metabolites</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of DWP 16001, Metformin</measure>
    <time_frame>0-144 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of DWP 16001, Metformin</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe of DWP 16001, DWP16001 Metabolites</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Fraction of the drug excreted into the urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR of DWP 16001</measure>
    <time_frame>0-144 hours</time_frame>
    <description>Renal clearance of the drug from plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>Tablets, Oral, once daily single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR</intervention_name>
    <description>Metformin IR 1000mg, Tablets, Oral, BID for 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001+Metformin IR</intervention_name>
    <description>Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male adults aged 19 to 50 years at the time of screening test

          -  55.0 kg ≤ Body weight ≤ 90.0 kg and 18.0 ≤ Body Mass Index (BMI) ≤ 27.0

          -  Written consent on voluntary decision of participation prior to the screening
             procedure after being fully informed of and completely understanding this study

          -  Eligible to participate in the study at the discretion of the investigator by physical
             examination, laboratory test, and history taking, etc.

        Exclusion Criteria:

          -  Current or history of clinically significant hepatic, renal, nervous, respiratory,
             endocrine, hemato-oncology, cardiovascular, urogenital, psychosis disorder

          -  Current or history of gastrointestinal disorders or prior history of gastrointestinal
             surgery that may affect safety and PK/PD assessment of the study drug

          -  Hypersensitivity or medical history of clinically significant hypersensitivity to a
             drug containing an ingredient of the investigational product (DWP16001),
             Dapagliflozin, Metformin or similar ingredient or other drugs (e.g., aspirin,
             antibiotics, etc.)

          -  Clinical laboratory test values are outside the accepted normal range at screening

          -  Other exclusive inclusion criteria, as defined in the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

